Home › Parathyroid Cancer › NCT03039439
Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors
Molecular and Immunohistochemical Profiling of Tumor From Patients With Parathyroid Tumors for Evaluation of Targeted Agents
Who can join
All ages · All sexes
Full eligibility criteria
Inclusion Criteria: * The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites). * All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated/treated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites). * All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity. * Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study. Exclusion Criteria: * Patients without tissue available for analysis.
About the study
This trial studies molecular and immunohistochemical profiling of tumors in patients with parathyroid tumors. Studying molecular and immunohistochemical profiling of tumors may help doctors avoid inconsistencies in diagnosis, unnecessary or incomplete surgery, surgical morbidity, psychological stress, and inadequate follow up.
What is being tested
- Biospecimen Collection (procedure)
- Laboratory Biomarker Analysis (other)
Sponsor: M.D. Anderson Cancer Center · Participants: 310 · Started: Nov 24, 2015
Contact the study team
- Nancy D. Perrier · Phone: 713-792-6940
Official record on ClinicalTrials.gov — NCT03039439
Locations in the U.S.
| Texas | M D Anderson Cancer Center, Houston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.